No Data
Sensus Healthcare, Inc. (NASDAQ:SRTS) CEO Joseph C. Sardano Sells 36,093 Shares
Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Rating) CEO Joseph C. Sardano sold 36,093 shares of the business's stock in a transaction dated Tuesday, August 9th. The shares were sold at an average pric
Sensus Healthcare Launches Upgrade To SRT-100 Vision System
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological con
Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Sensus Healthcare, Inc. (NASDAQ:SRTS) just released its second-quarter report and things are looking bullish. Statutory earnings performance was extremely strong, with revenue of US$12m beating e
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session. Carvana Co. (NYSE:CVNA) jumped 40.1% to close
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
Gainers Cooper-Standard Holdings Inc. (NYSE:CPS) jumped 69.6% to close at $8.53 on Friday following better-than-expected Q2 results.Intelligent Living Application Group Inc. (NASDAQ:ILAG) surged 64.4%
Sensus Healthcare, Inc. CEO Joe Sardano on Q2 2022 Results -- Earnings Call Transcript >SRTS
From Seeking Alpha: Sensus Healthcare, Inc. CEO Joe Sardano on Q2 2022 Results -- Earnings Call Transcript
What Type Of Shareholders Own The Most Number of Sensus Healthcare, Inc. (NASDAQ:SRTS) Shares?
If you want to know who really controls Sensus Healthcare, Inc. (NASDAQ:SRTS), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions will
Sensus Healthcare (SRTS) Receives a Buy from Maxim Group
In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Sensus Healthcare (SRTS – Research Report), with a price target of $20.00. The company's shares closed las
Sensus price target raised to $17.50 from $17 at Alliance Global Partners
Alliance Global Partners analyst Ben Haynor raised the firm's price target on Sensus Healthcare to $17.50 from $17 and keeps a Buy rating on the shares post the Q2 results. Management expects profitab
Top Midday Gainers
01:31 PM EDT, 08/05/2022 (MT Newswires) -- Cooper-Standard (CPS) reported Q2 sales jumped to $605.9 million from $533.2 million a year ago, beating the $576.1 million average analyst estimate compiled
Loading...